These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11748787)

  • 1. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
    Kennedy JS; Zagar A; Bymaster F; Nomikos G; Trzepacz PT; Gilmore JA; Rotelli MD; Breier A; Tollefson G
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S24-32. PubMed ID: 11748787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.
    Mintzer J; Faison W; Street JS; Sutton VK; Breier A
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S71-7. PubMed ID: 11748790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
    Street JS; Clark WS; Gannon KS; Cummings JL; Bymaster FP; Tamura RN; Mitan SJ; Kadam DL; Sanger TM; Feldman PD; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2000 Oct; 57(10):968-76. PubMed ID: 11015815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
    Street JS; Clark WS; Kadam DL; Mitan SJ; Juliar BE; Feldman PD; Breier A
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S62-70. PubMed ID: 11748789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
    Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW
    Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
    Cummings JL; Street J; Masterman D; Clark WS
    Dement Geriatr Cogn Disord; 2002; 13(2):67-73. PubMed ID: 11844887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.
    Kennedy JS; Bymaster FP; Schuh L; Calligaro DO; Nomikos G; Felder CC; Bernauer M; Kinon BJ; Baker RW; Hay D; Roth HJ; Dossenbach M; Kaiser C; Beasley CM; Holcombe JH; Effron MB; Breier A
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S33-61. PubMed ID: 11748788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
    De Deyn PP; Carrasco MM; Deberdt W; Jeandel C; Hay DP; Feldman PD; Young CA; Lehman DL; Breier A
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):115-26. PubMed ID: 14758577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
    Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
    Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
    Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
    Mulsant BH; Gharabawi GM; Bossie CA; Mao L; Martinez RA; Tune LE; Greenspan AJ; Bastean JN; Pollock BG
    J Clin Psychiatry; 2004 Dec; 65(12):1708-14. PubMed ID: 15641877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
    Tohen M; Sanger TM; McElroy SL; Tollefson GD; Chengappa KN; Daniel DG; Petty F; Centorrino F; Wang R; Grundy SL; Greaney MG; Jacobs TG; David SR; Toma V
    Am J Psychiatry; 1999 May; 156(5):702-9. PubMed ID: 10327902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.